Destiny Pharma appoints Professor Mark Wilcox to its Scientific Advisory Board

pharmafile | February 4, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Destiny Pharma, a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, has appointed Professor Mark Wilcox to its Scientific Advisory Board (SAB).

Professor Wilcox is a consultant microbiologist and Head of R&D in Microbiology at the Leeds Teaching Hospitals, as well as Lead on Clostridium difficile infection for Public Health England (PHE).  He also has advisory roles to UK SAGE (COVID-19), NHS England’s Infection Prevention & Control national team, and PHE’s Rapid Review Panel, reviewing the utility of infection prevention and control products for the NHS. Additionally, Professor Wilcox is a member of the NHS Antimicrobial Resistance Programme Board. 

Dr Bill Love, Chief Scientific Officer of Destiny Pharma, commented: “We are pleased to welcome Professor Wilcox, who is a recognised leader in UK/NHS infection prevention and control and a globally renowned expert in C. difficile infection.

“His knowledge compliments the existing expertise on our SAB as we plan for Phase III trials for our recently acquired asset, NTCD-M3, which is targeting the prevention of C. difficile infection recurrence. Professor Wilcox also brings an expert understanding of MRSA and COVID-19 hospital infections which is valuable insight for Destiny Pharma’s other preventative products in development, namely XF-73 and SPOR-COV.” 

Professor Mark Wilcox, added: “NTCD-M3 is a novel way to out-compete pathogenic C. difficile that can remain in the gut after antibiotic treatment of C. difficile infection.  I am greatly encouraged by the animal model and clinical trial data that support the ambition to use M3 to reduce the risk of recurrent C. difficile infection, which is the Achilles’ heel of antibiotic therapy.”

Related Content

No items found

Latest content